Last reviewed · How we verify
Cefradex (cefradine)
At a glance
| Generic name | cefradine |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | cefradine |
| Target | Matrix metalloproteinase-9 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Acute otitis media
- Bacterial infection due to Klebsiella pneumoniae
- Enterococcus Prostatitis
- Enterococcus Urinary Tract Infection
- Escherichia coli urinary tract infection
- Haemophilus Influenzae Acute Otitis Media
- Haemophilus influenzae pneumonia
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Infective otitis media
- Klebsiella Prostatitis
- Klebsiella cystitis
- Lower respiratory tract infection
- Pharyngitis
- Pneumonia
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Prostatitis
Common side effects
Key clinical trials
- Oral Versus Intravenous Antibiotic Prophylaxis Before Obstetric and Gynecological Procedures
- Efficacy of Oxybutynin in Paediatric Cystitis (PHASE4)
- Operational Research Management for Children With Severe Pneumonia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefradex CI brief — competitive landscape report
- Cefradex updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI